Edgewise Therapeutics (EWTX) is considered one of the best small-cap biotech stocks to buy by analysts, reporting heightened R&D activity in Q3 2025. With advancements in muscular dystrophy and cardiac programs, the company saw an increase in R&D expenses to $37.5 million and closed the quarter with $563.3 million in cash balances.

Despite a net loss of $40.7 million in Q3, Edgewise Therapeutics (EWTX) continues to focus on developing new therapies for muscular dystrophies and serious cardiac conditions. The company’s progress in clinical trials for EDC-15400, EDC-7500, and sevasemten programs led to increased expenses, but its cash reserves provide support for ongoing development.

As a biopharmaceutical company, Edgewise Therapeutics (EWTX) aims to address unmet medical needs in muscular dystrophies and cardiac conditions. While it presents investment potential, other AI stocks may offer greater upside. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is available.

For more information on potential investment opportunities, explore the 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential. Disclosure: None.

Read more at Yahoo Finance: Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025